AstraZeneca
AZN
343 hedge funds and large institutions have $6.87B invested in AstraZeneca in 2013 Q3 according to their latest regulatory filings, with 49 funds opening new positions, 140 increasing their positions, 93 reducing their positions, and 34 closing their positions.
181% more call options, than puts
Call options by funds: $140M | Put options by funds: $49.7M
80% more funds holding in top 10
Funds holding in top 10: 5 → 9 (+4)
51% more repeat investments, than reductions
Existing positions increased: 140 | Existing positions reduced: 93
44% more first-time investments, than exits
New positions opened: 49 | Existing positions closed: 34
18% more capital invested
Capital invested by funds: $5.84B → $6.87B (+$1.03B)
4% more funds holding
Funds holding: 331 → 343 (+12)
0.6% more ownership
Funds ownership: 9.87% → 10.47% (+0.6%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Boston Partners
Boston,
Massachusetts
|
+$127M |
| 2 |
Wellington Management Group
Boston,
Massachusetts
|
+$92.1M |
| 3 |
PI
Putnam Investments
Boston,
Massachusetts
|
+$85.1M |
| 4 |
ClearBridge Investments
New York
|
+$81.3M |
| 5 |
Capital Research Global Investors
Los Angeles,
California
|
+$58.8M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Arrowstreet Capital
Boston,
Massachusetts
|
-$151M |
| 2 |
Allianz Asset Management
Munich,
Germany
|
-$107M |
| 3 |
Ameriprise
Minneapolis,
Minnesota
|
-$48.8M |
| 4 |
IG
ING Group
Amsterdam,
Netherlands
|
-$37.4M |
| 5 |
MAA
Managed Account Advisors
Jersey City,
New Jersey
|
-$31M |
AZN Hedge Fund Activity: Q3 2013 in Review
343 of the 3,085 institutional investors tracked by Wall St. Rank reported a position in AstraZeneca (AZN) for Q3 2013, worth a combined $6.87B — up 18% from $5.84B a quarter earlier.
Buyers outnumbered sellers: 49 funds opened new AZN positions and 34 closed out — a net gain of 15 holders — while 140 added to existing stakes and 93 trimmed.
The largest buyer was Boston Partners, adding an estimated $127M. The largest seller was Arrowstreet Capital, cutting an estimated $151M.
- 343 institutional investors held AstraZeneca (AZN) as of Q3 2013, up from 331 in Q2 2013.
- Funds reported $6.87B of AstraZeneca stock for Q3 2013, up 18% quarter-over-quarter.
- 49 funds opened new AstraZeneca positions in Q3 2013 and 34 closed out, a net change of +15 holders.
- The largest AstraZeneca buyer in Q3 2013 was Boston Partners, an estimated $127M added.
- The largest AstraZeneca seller in Q3 2013 was Arrowstreet Capital, an estimated $151M sold.
Based on aggregated 13F filings for Q3 2013.